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Lobular alveolar hyperplasiaAbstract Background: Breast cancer is the most common type of cancer and leading cause of can-
cer death in women. Breast cancer and cancer related diseases have been treated using surgery, che-
motherapy, and radiation therapy, or a combination of these. Despite these therapeutic options,
cancer remains associated with high mortality. Traditional medicine which involves the use of herbs
has been used to treat various types of cancer and this has been found to be effective with minimal
or no side effects.
Aim: This research was aimed at evaluating the potential chemopreventive effect of an ethanolic
extract of Annona muricata leaves on 7,12-dimethylbenzeneanthracene (DMBA)-induced cell prolif-
eration in the breast tissues of female albino mice.
Materials and methods: A. muricata leaves, thirty (30) female albino mice, and 7,12-dimethylben-
zeneanthracene (DMBA) were used for this study. Crude extraction protocol was employed in the
preparation of an ethanolic extract of A. muricata leaves. Qualitative and quantitative phytochem-
ical screening of an ethanolic extract of A. muricata leaves was carried out using standard protocol.
Agarose gel electrophoresis was used to analyze deoxyribonucleic acid (DNA) extracted from the
breast tissues of experimental mice while hematoxylin and eosin staining was used for histological
assay.
Results: Phytochemical screening revealed the presence of terpenoid, steriod, ﬂavonoids, cardiac
glycoside, tannin, phenol, alkaloid, and reducing sugar. Phenol was quantitatively determined to be
present in the highest amount. DNA smears obtained from agarose gel electrophoresis suggested
possible DMBA-induced damage which was signiﬁcantly prevented owing to the effect of the leaf
extract of A. muricata leaves. Histological assay revealed the presence of DMBA induced lobular
alveolar hyperplasia, adenomatoid hyperplasia, ﬁbro adipose stroma, and proliferating sebaceous
gland in the histological sections of the breast tissues of treated mice, however, these changes were
found to vary in occurrence among the different groups of treated animals.
328 J.B. Minari, U. OkekeConclusion: This study has shown that the leaf extract of A. muricata could be used as a prophy-
lactic measure against DMBA-induced cell proliferation in the breast tissues of female albino mice.
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Cancer is a multifactorial disease arising from the accumula-
tive effects of gene products of mutant proto-oncogenes,
tumor suppressor genes and DNA repair genes, leading to
the uncontrolled growth and spread of cancer cells [1,2]. There
are over 100 different types of cancer, and each is classiﬁed by
the type of cell that is initially affected, and these include cer-
vical cancer, skin cancer, leukemia, lung cancer, prostate can-
cer, and so on [3].
Breast cancer represents the most common neoplastic dis-
ease in females, accounting for up to one third of new diagno-
ses of women’s cancer in certain regions of the world [4]. In
developing countries traditionally known for low incidence
of breast cancer, increase in both incidence and mortality
has been recently detected [5]. Azubuike and Okwuokei [6]
observed that in Nigeria, the peak age of breast cancer is about
ten years earlier than the experience of many western women
and were attributed to increasing adoption of western life style
and diet. Contrary to previous reports indicating breast cancer
as the second leading cause of cancer deaths, breast cancer is
now the leading cause of cancer deaths in Nigerian women
[7–9].
Breast cancer and cancer related diseases have been treated
using surgery, chemotherapy, and radiation therapy, or a com-
bination of these. But despite these therapeutic options, cancer
remains associated with high mortality [10]. This is basically
due to difﬁculties in early diagnosis, exorbitant cost of treat-
ment, with the often late presentation of breast cancer that
generally characterizes cancer diagnosis among Nigerian and
other African women [10–13]. Owing to these several short-
comings, there is a need for better therapeutic options which
will increase the chances of survival of breast cancer patients
with minimal or no side effects of treatment. Early diagnoses
of breast cancer and its prevention have been suggested as a
better means of managing breast cancer because about 5%
of human breast cancers have been attributed to inheritance
of breast cancer susceptibility genes [2,14]. Therefore, people
with familial history of breast cancer have better options of
diagnosing and preventing its occurrence within their life time.
Among the major problems of breast cancer therapy is the
fact that a majority of patients suffering from the disease can-
not afford the high cost of therapy [15]. It has also been discov-
ered that more than 70% of all cancer deaths occurred in low
and middle-income earners [16]. Nigeria as one of the countries
found in the tropics is rich with plants that have been found to
possess anticancer therapeutic activity [10]. Annona muricata
commonly called soursop or ‘‘sharp sharp’’ is a small erect
evergreen tropical fruit tree plant belonging to the family
Annonaceae, growing 5–6 m in height [17]. It is one of the eas-
ily found plants used traditionally in treating cancer. The leaf
decoction is usually taken to lessen the symptoms of cancer
[18].In order to develop a better and cheaper means of prevent-
ing breast cancer in people liable to suffering the disease in
their life time, this work was therefore aimed at evaluating
the chemopreventive effect of an ethanolic extract of A. muri-
cata leaves on 7,12-dimethylbenzeneanthracene (DMBA)-
induced cell proliferation in the breast tissues of female albino
mice.
2. Materials and methods
2.1. Experimental animals
The 30 adult mice used for this study were obtained from the
Nigeria Institute of Medical Research, Lagos, Nigeria. The
animals were housed in standard clean mice cages at 25 C,
fed with standard pellet and tap water ad libitum. They were
maintained under uniform conditions of natural photo period
(12 h light/dark cycle) and humidity (61–95%).
2.2. Plant collection and identiﬁcation
Leaves of A. muricata were collected in the month of May
2013, from the botanical garden of the University of Lagos,
Lagos, Nigeria. Leaves were identiﬁed and conﬁrmed taxo-
nomically at the Department of Botany, University of Lagos,
Lagos, Nigeria. A voucher specimen number LUH 6070 of
the plant was deposited in the Herbarium of the same
department.
2.3. Plant preparation and extraction
A. muricata leaves were washed in a running tap and air-dried
in the Cell Biology and Genetics laboratory, University of
Lagos. The dried leaves were later blended using an electric
blender which had been sterilized with 70% ethanol. The leaf
extract was obtained using Crude Extraction Protocol. About
350 g of A. muricata powder was soaked in 70% ethanol for
72 h. This was later ﬁltered using a sieve. The ﬁltrate was con-
centrated using a water bath set at 40 C. The ﬁnal mass of
concentrated extract obtained was 40 g. The concentrate was
used to prepare the different concentrations used for the exper-
iment and phytochemical screening.
3. Methodology
At the commencement of this work, thirty (30) adult female
albino mice weighing between 21 and 28 g, were divided into
5 groups, each group had 6 mice. The experimental groups
received different concentrations of an ethanolic extract of
A. muricata prepared with respect to the LD50 result as docu-
mented by Arthur et al. [17]. Mice were treated with increasing
doses of extract.
Table 2 Quantitative analyses of selected phytochemicals
present in an ethanolic extract of Annona muricata leaves.
S. No. Phytochemical Annona muricata (mg/100 g)
1 Phenol 162.99
2 Cardiac glycosides 12.92
3 Tannin 121.98
4 Alkaloid 13.74
5 Flavonoids 16.26
Table 1 Qualitative analysis of an ethanolic extract of Annona
muricata leaves.
S. No. Phytochemical components Ethanolic extract
1 Saponin 
2 Terpenoid +
3 Steroid +
4 Flavonoids +
5 Cardiac glycoside +
6 Tannin +
7 Phenol +
8 Phlobatannin 
9 Alkaloid +
10 Reducing sugar +
Key: (+), Presence of phytochemical; (), Absence of
phytochemical.
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of DMBA+ 200 mg/ml/day of extract.
Group MB: Mice treated with 20 mg/ml/week
of DMBA+ 100 mg/ml/day of extract.
Group MC: Mice treated with 20 mg/ml/week
of DMBA+ 50 mg/ml/day of extract.
Group NC (Negative Control): Mice treated with 20
mg/ml/week of DMBA only.
Group PC (Positive Control): Mice treated with distilled
water only.
DMBA and extract were given intragastrically by gavage
using a cannula ﬁtted to a feeding needle. Treatment of ani-
mals lasted for six (6) weeks. The experimental and control
animals were carefully checked daily and their weight taken
weekly. Each mouse had 6 pairs of mammary glands that were
checked by inspection, touching and palpitation [4]. Mice were
sacriﬁced at the end of the sixth week by cervical dislocation.
The breast tissues from each animal were sliced off and divided
into two portions using a surgical blade. One portion was ﬁxed
in formalin saline for histology using hematoxylin and eosin
staining while the other portion was ﬁxed in ethanol for aga-
rose gel electrophoresis. The work was carried out in the ani-
mal house of the University of Lagos, Lagos, Nigeria in
accordance with the Code of Ethics of The World Medical
Association (Declaration of Helsinki) for animal experiment
with consent from the University of Lagos Ethics Committee
guidelines for experiments with whole animals [19].
3.1. Phytochemical screening
This was carried out using standard procedures in accordance
with Vimala et al. [20].
3.2. DNA extraction
The DNA extraction protocol used for this study was a mod-
iﬁed procedure of Nishiguchi et al. [21].
Group MA: Mice treated with 20 mg/ml/week
of DMBA+ 200 mg/ml/day of extract.
Group MB: Mice treated with 20 mg/ml/week
of DMBA+ 100 mg/ml/day of extract.
Group MC: Mice treated with 20 mg/ml/week
of DMBA+ 50 mg/ml/day of extract.
Group NC (Negative Control): Mice treated with 20
mg/ml/week of DMBA only.
Group PC (Positive Control): Mice treated with distilled
water only.
4. Results
Table 1 shows the result obtained from the qualitative phyto-
chemical screening of the ethanolic extract of A. muricata leaf.
Phytochemical screening revealed that terpenoid, steroid,
ﬂavonoids, cardiac glycoside, tannin, phenol, alkaloid, and
reducing sugar were present while phlobatannin and saponin
were absent.
The quantitative phytochemical screening of selected
phytochemicals present in the ethanolic extract of Annonamuuricata is shown in Table 2. Phenol was discovered to be
present in the highest amount while cardiac glycoside was
found to be in the lowest amount.
The effects of an ethanolic extract of A. muricata leaves on
the survival rate of mice administered with DMBA are shown
in Fig. 1. No death was recorded in any group during the ﬁrst
2 weeks. The highest number of deaths was recorded in NC in
the ﬁfth week. No death was recorded in MB throughout the
6 weeks of this experiment.
Plate 2 is the genomic DNA smear obtained from the elec-
trophoresis of deoxyribonucleotides (DNAs) obtained from
the breast tissues of mice from different experimental groups.
Genomic DNA smear from PC had normal smear typical of
agarose gel electrophoresis. But smears displayed by other
groups deviated from normal; with the deviation being highest
in NC. Genomic DNA smear obtained from PC and MB are
similar and have better smears compared to NC and MC.
DNA obtained from MA showed no smear.
The histological section of the breast tissues of mouse in the
positive control is shown in Plate 3i. This revealed the presence
of normal epidermal tissue, sweat glands, sebaceous gland,
alveolar duct and terminal bronchiole.
Plate 3ii shows the histological section of the breast tissues
of DMBA-induced cell proliferation in mouse from the
negative control group. Normal keratinocytes, sebaceous
glands, ecrine glands and subdermal layer with prominent
DMBA-induced lobular alveolar hyperplasia were seen to be
present.
Plate 4i reveals the histological section of the breast tissue
of DMBA-induced cell proliferation of mice that were treated
with 200 mg/ml of extract. The presence of DMBA-induced
330 J.B. Minari, U. Okekelobular alveolar hyperplasia, ﬁbrocystic change and DMBA-
induced ﬁbroadenomatoid hyperplasia were identiﬁed in Plate
4i while lobular alveolar hyperplasia and ﬁbro adipose stroma
were identiﬁed in Plate 4ii.
The histological section of the breast tissue of DMBA-
induced cell proliferation in mouse that was treated with
100 mg/ml of extract is shown in Plate 5. The section revealed
the presence of DMBA-induced lobular alveolar hyperplasia.
Plate 6 shows the histological section of the breast tissue of
DMBA-induced cell proliferation in mouse that was treated
with 50 mg/ml of ethanolic extract of A. muricata. This reveals
the presence of proliferating sebaceous glands and lobular
alveolar hyperplasia.Plate 1 DMBA induced-papilloma on the hind limbs of mouse tre
induced papilloma.
Figure 1 Effects of an ethanolic extract of Annona muricata leaves5. Discussion
Breast cancer is the most common type of cancer and the lead-
ing cause of cancer death in Nigerian women [7,8]. Owing to
this fact, in addition to a long latency period of many years
prior to the development of metastatic disease, this form of
cancer could be identiﬁed as an ideal target for chemopreven-
tion and/or early intervention. A general concept put forward
by several researchers is that the anticancer activity of com-
pounds which are typically present in plants at sub-pharma-
ceutical doses could synergize to delay or disrupt the
development of aggressive disease [22,23]. The chemopreven-
tive effect of an ethanolic extract of A. muricata leaf extractated with DMBA only. Arrows indicate the location of DMBA
on the survival rate of DMBA-induced cell proliferation in mice.
Plate 2 Genomic DNA smear obtained from the electrophoresis DNAs obtained from the breast tissues of DMBA-induced cell
proliferation in mice.
(i) PC (HE-100X) (ii) NC (HE-100X) 
Plate 3 Histological sections of the breast tissues of mice from the positive (PC) and negative control (NC) showing the alveolar duct
and terminal bronchiole in (i) and DMBA-induced lobular alveolar hyperplasia in (ii).
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cancer in mice was evaluated. DMBA is a well-known potent
carcinogen which has been used to induce carcinogenesis in
the mammary gland or skin of experimental rodents such as
rat and mouse [4,24–27].
The visible evidence of 7,12-dimethylbenz[a]anthracene
administration (DMBA) induced-papilloma was seen in the
hind limbs of mouse treated with DMBA only (Plate 1) about
4 weeks after DMBA administration. This occurred earlier
than reported by Barros et al. [4]. This could be owing to the
fact that the modiﬁed method of Barros et al. [4] used for this
study was of higher concentration. The high death rate
recorded in the ﬁfth week among the group of mice treated
with DMBA only might be attributed to the toxicity of the car-
cinogen. A recent study that focused on the immunotoxicity ofDMBA given to experimental animals to induce mammary
gland showed that DMBA elicits immunotoxicity in the spleen,
thymus and bone marrow [28].
The deviation from normal displayed by the genomic DNA
smears obtained after electrophoresis, especially in NC (Plate
2), might have arisen as a result of DMBA-induced deoxyribo-
nucleic acid (DNA) damage or mutation. This is in concor-
dance with the report of Nebert et al. and Rundle et al.
[29,30] who described the mechanism of action of DMBA to
involve up-regulation of cytochrome P450 enzymes that
metabolize DMBA into a mutagenic epoxide intermediate
which readily forms DNA-adducts that are associated with
DNA mutations and the malignant transformation that leads
to carcinogenesis. As cancer cells usually have mutations in
genes regulating DNA damage responses or repair pathways,
(i) MA (HE-100X) (ii) MA (HE-100X) 
Plate 4 Histological sections of the breast tissues of DMBA-induced cell proliferation in mouse treated with 200 mg/ml showing
ﬁbroadenomatoid hyperplasia in (i) and ﬁbro adipose stroma in (ii).
MC (HE-100X)
Plate 6 Histological section of the breast tissue of DMBA
induced cell proliferation in mouse treated with 50 mg/ml of
extract showing the presence of lobular alveolar hyperplasia and
proliferating sebaceous gland.
 MB (HE-100X) 
Plate 5 Histological section of the breast tissue of DMBA-
induced cell proliferation in mouse treated with 100 mg/ml of
extract showing the presence of lobular alveolar hyperplasia.
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more susceptible to cell cycle arrest and death from treatment
with carcinogenic agents than normal cells [2,31].The similarity between the genomic DNA smears displayed
by DNAs obtained from PC and MB might be due to the pre-
vention of excessive DMBA-induced damage to DNA by an
ethanolic extract of A. muricata leaves at a concentration of
100 mg/ml (Plate 2). Many chemotherapeutic agents such as
plant-derived compounds have been shown to exert their ther-
apeutic effect by directly interacting with DNA or DNA-bind-
ing proteins [31,32]. This interaction triggers DNA damage
signaling pathways resulting in the inhibition of cell prolifera-
tion or the induction of apoptosis, depending on the extent of
the damage [33]. However, the similarity between smears dis-
played by the DNAs obtained from MC and NC (Plate 2) sug-
gests the plant extract’s inability to prevent DMBA-induced
DNA damage at a dose of 50 mg/ml. Therefore, the extract
could be said to have acted in such a way as to prevent or
reduce excessive DMBA-induced DNA damage. The preven-
tive effect of an ethanolic extract of A. muricata leaves against
DMBA-induced DNA damage could be owing to the presence
of the various secondary metabolites (tannins, terpenoids, car-
diac glycosides (CGs), and ﬂavonoids) discovered from the
phytochemical screening of the ethanolic extract of A. muricata
(Table 1).
Previous studies have shown that tannins, terpenoids, car-
diac glycosides (CGs), and ﬂavonoids possess anticancer activ-
ities [34–41]. Epidemiologic evidence suggested that breast
cancer patients treated with cardiac glycosides had a signiﬁ-
cantly lower mortality rate, and their cancer cells had more
benign characteristics than those from patients not treated
with it [34]. Phenol was determined to be quantitatively present
in the highest amount (Table 2), this might have accounted for
the preventive effect of the extract on DMBA-induced cell pro-
liferation. This is in agreement with the previous studies show-
ing the anti-proliferative effects of herbal polyphenols, in
various human cancer cell lines [42–44].
The presence of DMBA-induced lobular alveolar hyperpla-
sia, and DMBA-induced ﬁbroadenomatoid hyperplasia in the
histological sections of the breast tissues of mice treated with
DMBA (Plates. 3ii, 4, 5, and 6) suggests a neoplastic transfor-
mation which is an indication of DMBA-induced cell prolifer-
ation [45]. DMBA-induced ductal hyperplasia has been
discovered to be a physiologic precursor to the development
of ductal carcinoma in situ [46]. Furthermore, DMBA-induced
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ductal carcinomas, ﬁbroadenomas, adenomas, and papillomas
[4]. However, these changes were found to vary in occurrence
among the different groups used for the present study. These
variations might be due to the preventive effect of the different
concentrations of extract administered to mice. Terminal end
buds had been shown to be preferential targets of DMBA
effects (DMBA–DNA linking) in the neoplastic transforma-
tion of the mammary gland [26]. The presence of proliferating
cells in the stroma as well as among the epithelial and myoep-
ithelial cells (Plate 4ii) strongly suggests that the carcinogen
acts on different cells in the breast tissue and, although the
stroma itself does not undergo neoplastic transformation, it
plays an important role in the carcinogenic process [47].
6. Conclusion
The present study showed that the ethanolic extract of A. muri-
cata leaves can be used as a preventive measure against
DMBA-induced breast cell proliferation in the breast tissues
of female albino mice. Agarose gel electrophoresis showed that
the plant extract prevented DMBA-induced DNA damage to
some extent. Histological assay revealed the presence of a neo-
plastic transformation which suggests the presence of cells
undergoing the initial proliferative stage preceding carcinogen-
esis. The knowledge obtained from this study can be exploited
by person(s) suspected to be linked with familial history of
breast cancer. Nevertheless, further studies and more research
need to be done to optimize the quality of extract, effective
dose and its speciﬁcity on breast cancer susceptibility genes.
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